» Articles » PMID: 34692685

The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells

Overview
Specialty Cell Biology
Date 2021 Oct 25
PMID 34692685
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) lists as the second most lethal cancer for men in western countries, and androgen receptor (AR) plays a central role in its initiation and progression, which prompts the development of androgen deprivation therapy (ADT) as the standard treatment. Prostate tumor microenvironment, consisting of stromal cells and extracellular matrix (ECM), has dynamic interactions with PCa epithelial cells and affects their growth and invasiveness. Studies have shown that both genomic and non-genomic AR signaling pathways are involved in the biological regulation of PCa epithelial cells. In addition, AR signaling in prostate stroma is also involved in PCa carcinogenesis and progression. Loss of AR in PCa stroma is clinically observed as PCa progresses to advanced stage. Especially, downregulation of AR in stromal fibroblasts dysregulates the expression levels of ECM proteins, thus creating a suitable environment for PCa cells to metastasize. Importantly, ADT treatment enhances this reciprocal interaction and predisposes stromal cells to promote cell invasion of PCa cells. During this process, AR in PCa epithelium actively responds to various stimuli derived from the surrounding stromal cells and undergoes enhanced degradation while elevating the expression of certain genes such as MMP9 responsible for cell invasion. AR reduction in epithelial cells also accelerates these cells to differentiate into cancer stem-like cells and neuroendocrine cells, which are AR-negative PCa cells and inherently resistant to ADT treatments. Overall, understanding of the cross talk between tumor microenvironment and PCa at the molecular level may assist the development of novel therapeutic strategies against this disease. This review will provide a snapshot of AR's action when the interaction of stromal cells and PCa cells occurs.

Citing Articles

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance.

Li C, Cheng D, Li P Front Oncol. 2025; 15:1542811.

PMID: 40008000 PMC: 11850250. DOI: 10.3389/fonc.2025.1542811.


Efficacy of Chlorogenic Acid in Treating Tripterygium Glycoside-Induced Asthenozoospermia in Rats and Its Possible Mechanisms.

Chen L, Bello-Onaghise G, Chen M, Li S, Zhang Y, Wang H Vet Sci. 2025; 12(1).

PMID: 39852941 PMC: 11768533. DOI: 10.3390/vetsci12010066.


Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.

Chen L, Xu Y, Wang Y, Ren Y, Dong X, Wu P Mol Cancer. 2024; 23(1):229.

PMID: 39395984 PMC: 11470719. DOI: 10.1186/s12943-024-02137-1.


The mA regulators in prostate cancer: molecular basis and clinical perspective.

Cao Y, Jia M, Duan C, Yang Z, Cheng B, Wang R Front Pharmacol. 2024; 15:1448872.

PMID: 39268470 PMC: 11391310. DOI: 10.3389/fphar.2024.1448872.


Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment.

Ak C, Sayar Z, Thibault G, Burlingame E, Kuykendall M, Eng J iScience. 2024; 27(9):110668.

PMID: 39246442 PMC: 11379676. DOI: 10.1016/j.isci.2024.110668.


References
1.
Placencio V, Li X, Sherrill T, Fritz G, Bhowmick N . Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS One. 2010; 5(9):e12920. PMC: 2944821. DOI: 10.1371/journal.pone.0012920. View

2.
Nakazawa M, Antonarakis E, Luo J . Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer. 2014; 5(5):265-73. PMC: 4167475. DOI: 10.1007/s12672-014-0190-1. View

3.
Liu Y, Karaca M, Zhang Z, Gioeli D, Earp H, Whang Y . Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene. 2010; 29(22):3208-16. PMC: 2880659. DOI: 10.1038/onc.2010.103. View

4.
Lin T, Izumi K, Lee S, Lin W, Yeh S, Chang C . Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013; 4:e764. PMC: 3763432. DOI: 10.1038/cddis.2013.270. View

5.
Palethorpe H, Leach D, Need E, Drew P, Smith E . Myofibroblast androgen receptor expression determines cell survival in co-cultures of myofibroblasts and prostate cancer cells . Oncotarget. 2018; 9(27):19100-19114. PMC: 5922380. DOI: 10.18632/oncotarget.24913. View